NYXH
Nyxoah S.A.NASDAQHealthcare$3.56+12.30%ClosedMarket Cap: $132.9M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.52
P/S
11.52
EV/EBITDA
-1.57
DCF Value
$-37.10
FCF Yield
-60.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
63.1%
Operating Margin
-844.4%
Net Margin
-899.1%
ROE
-135.3%
ROA
-131.8%
ROIC
-90.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $5.6M | $-23.5M | $-0.59 |
| FY 2025 | $10.0M | $-90.1M | $-2.37 |
| Q3 2025 | $2.0M | $-23.6M | $-0.63 |
| Q2 2025 | $1.3M | $-20.6M | $-0.55 |
Analyst Ratings
View AllCantor FitzgeraldOverweight
2026-03-23StifelBuy
2026-03-20StifelBuy
2026-01-29Piper SandlerOverweight
2025-11-14StifelBuy
2025-04-21Company Info
Sector
Healthcare
Industry
—
Country
BE
Exchange
NASDAQ
Beta
0.87
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.